BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

BioCryst said it expects ORLADEYO to reach $1B peak sales, citing payer mix of ~60% commercial, 20% Medicare Part D and 20% Medicaid and gross-to-net around 15% last year. Pediatric ORLADEYO launch was delayed by a batch manufacturing issue, not safety-related. In Phase 3, navenibart ALPHA-ORBIT enrollment should finish by end-June; top-line data due Q3 next year, with a likely 2H 2028 launch. BioCryst reported pro forma cash of $330M and expects profitability this year and next.

Amneal Pharmaceuticals said the FDA approved its ready-to-use romidepsin injection solution (27.5 mg/5.5 mL) in single-dose vials. The drug received Competitive Generic Therapy (CGT) designation, granting Amneal 180 days of market exclusivity. Amneal said the product references a Teva romidepsin liquid previously withdrawn. IQVIA data cited about $78 million in U.S. sales for the prior lyophilized form.

Amneal Pharmaceuticals said the U.S. FDA approved its romidepsin injection solution (27.5 mg/5.5 mL) in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy status, granting 180 days of market exclusivity, and references a former Teva formulation. IQVIA data cited by Amneal put U.S. sales of romidepsin lyophilized powder at about $78 million for 12 months ended April 2026.

BioCryst Pharmaceuticals is set to present new real-world evidence at the ISPOR 2026 conference, highlighting the persistent challenges faced by children with hereditary angioedema (HAE). The presentation will underscore the significant burden this condition places on young patients, offering insights into the specific difficulties and impact on their lives. This data aims to shed light on the realities of living with HAE for the pediatric population.

BioCryst Pharmaceuticals secured a European licensing deal for its investigational HAE therapy, navenibart, with an Irish affiliate of Neopharmed Gentili. The agreement includes a US$70 million upfront payment, potential milestones up to US$275 million, and tiered royalties, providing a capital infusion for BioCryst's Phase 3 development. While this deal strengthens short-term funding and leverages an existing European infrastructure, the company's long-term success still hinges on ORLADEYO's performance and navenibart's trial outcomes amidst rising competition in the HAE market.

One executive's option-linked sale may look large on paper, but the broader context tells a more nuanced story.